Psoriatic arthritis and obesity: the role of anti-IL-12/IL-23 treatment.
Biological therapy
Interleukin inhibitor
MDA in PsA
Obesity
Psoriatic arthritis
Therapeutic response
Journal
Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
11
04
2019
accepted:
25
06
2019
revised:
21
06
2019
pubmed:
3
7
2019
medline:
12
2
2020
entrez:
3
7
2019
Statut:
ppublish
Résumé
Patients with psoriatic arthritis (PsA) have an increased prevalence of obesity, but mechanisms underlying this association remain unknown and it is unclear if obesity is the cause or effect of PsA. For PsA patients, comorbid obesity may influence their clinical response to systemic treatment, and especially targeted immunomodulators such as anti-tumor necrosis factor (TNF)α. Weight gain has also been associated with anti-TNFα treatment. Consequently, modification of the therapeutic approach may be needed for patients with an inadequate response to TNFα inhibitors. In recent years, interleukin (IL)-12/IL-23 inhibitors have entered clinical practice as a new class of drug for the treatment of PsA, with some data suggesting a lower effect of body weight on their effectiveness. Recent findings demonstrate effective and sustained responses in patients with PsA to ustekinumab, an IL-12/IL-23 inhibitor. This narrative review critically discusses the link between PsA, obesity, and response to therapy. The current role of ustekinumab in this setting is also discussed.
Identifiants
pubmed: 31264033
doi: 10.1007/s10067-019-04663-6
pii: 10.1007/s10067-019-04663-6
doi:
Substances chimiques
Antirheumatic Agents
0
Biological Products
0
Interleukin-23
0
Interleukin-12
187348-17-0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2355-2362Références
Br J Nutr. 2004 Sep;92(3):347-55
pubmed: 15469638
Aliment Pharmacol Ther. 2005 Nov;22 Suppl 2:3-10
pubmed: 16225463
Eur Cytokine Netw. 2006 Mar;17(1):4-12
pubmed: 16613757
J Eur Acad Dermatol Venereol. 2008 Mar;22(3):341-4
pubmed: 18005022
Ann Rheum Dis. 2008 Jan;67(1):1-4
pubmed: 18077541
Pharmacol Res. 2008 Apr;57(4):290-5
pubmed: 18400510
Int J Obes (Lond). 2009 Jan;33(1):151-6
pubmed: 18982006
Arch Dermatol. 2010 Jul;146(7):721-6
pubmed: 20644032
J Eur Acad Dermatol Venereol. 2011 Sep;25(9):1007-11
pubmed: 21492252
Arthritis Care Res (Hoboken). 2011 Dec;63(12):1729-35
pubmed: 21905258
Dermatol Ther. 2011 Jul-Aug;24(4):446-51
pubmed: 21910803
Int J Inflam. 2011;2011:376909
pubmed: 21941676
Rheumatology (Oxford). 2012 Mar;51(3):552-6
pubmed: 22120603
Arthritis Care Res (Hoboken). 2013 Jan;65(1):141-7
pubmed: 22514189
Ann Rheum Dis. 2012 Aug;71(8):1267-72
pubmed: 22562978
Ann Rheum Dis. 2012 Aug;71(8):1273-7
pubmed: 22586165
Am J Prev Med. 2012 Jun;42(6):563-70
pubmed: 22608371
Nat Immunol. 2012 Jul 19;13(8):707-12
pubmed: 22814340
Br J Dermatol. 2013 May;168(5):1124-7
pubmed: 23320916
Gastroenterology. 2013 Aug;145(2):366-74.e1-3
pubmed: 23597726
Ann Rheum Dis. 2014 Jun;73(6):1157-62
pubmed: 23771989
Clin Rheumatol. 2014 Jun;33(6):833-9
pubmed: 23959447
Arthritis Care Res (Hoboken). 2014 Apr;66(4):600-7
pubmed: 24115739
Eur J Nutr. 2014 Apr;53(3):951-61
pubmed: 24173963
Ann Rheum Dis. 2015 May;74(5):813-7
pubmed: 24431392
Expert Opin Biol Ther. 2014 Jun;14(6):749-56
pubmed: 24661040
Front Immunol. 2014 Aug 12;5:368
pubmed: 25161652
Int J Rheum Dis. 2016 Jul;19(7):672-7
pubmed: 25196858
J Diabetes Res. 2015;2015:648239
pubmed: 25650072
Arthritis Care Res (Hoboken). 2015 Dec;67(12):1739-49
pubmed: 26097039
Clin Exp Rheumatol. 2015 Sep-Oct;33(5 Suppl 93):S115-8
pubmed: 26471946
Rheum Dis Clin North Am. 2015 Nov;41(4):545-68
pubmed: 26476218
Rheum Dis Clin North Am. 2015 Nov;41(4):677-98
pubmed: 26476226
RMD Open. 2015 Jun 29;1(1):e000012
pubmed: 26509048
Autoimmun Rev. 2016 May;15(5):447-50
pubmed: 26808074
Reumatol Clin. 2016 Nov - Dec;12(6):307-312
pubmed: 26830438
Adipocyte. 2016 Jan 25;5(3):275-82
pubmed: 27617173
Rheumatology (Oxford). 2016 Dec;55(12):2191-2199
pubmed: 27651526
J Rheumatol. 2017 Apr;44(4):437-443
pubmed: 28202737
N Engl J Med. 2017 Mar 9;376(10):957-970
pubmed: 28273019
Expert Rev Clin Pharmacol. 2017 Aug;10(8):899-910
pubmed: 28490202
J Clin Med. 2017 Jul 14;6(7):null
pubmed: 28708082
Clin Rheumatol. 2018 Feb;37(2):397-405
pubmed: 29302829
Eur J Rheumatol. 2017 Dec;4(4):272-277
pubmed: 29308283
Clin Rheumatol. 2018 Mar;37(3):579-586
pubmed: 29313273
Clin Rheumatol. 2018 Mar;37(3):667-675
pubmed: 29411182
Int J Mol Sci. 2018 Feb 09;19(2):null
pubmed: 29425183
J Clin Rheumatol. 2018 Oct;24(7):381-384
pubmed: 29509560
Joint Bone Spine. 2019 Mar;86(2):173-183
pubmed: 29635017
J Med Life. 2018 Jan-Mar;11(1):69-74
pubmed: 29696068
PLoS One. 2018 May 17;13(5):e0195123
pubmed: 29771924
Postepy Dermatol Alergol. 2018 Aug;35(4):360-366
pubmed: 30206447